Hyphens Pharma International nearly doubled its net profit for the first quarter of 2024 to $2.7m backed by robust revenue during the period.
“The Specialty Pharma portfolio continues to serve as the primary catalyst for growth in Q1 2024. It has rebounded from supply chain disruptions in H1 2023,” the company noted. “At the same time, we observed similar quarter-on-quarter trending with the Proprietary Brands segment, a reduction in quarter-on-quarter sales could be attributed to the same reason above,” the company said.
The company’s gross profit also improved 32.8% to $17.4m during the quarter. However, the gross profit margin declined to 36.3% due to continued cost pressure and a higher sales mix of products carrying a lower margin.Recently, Hyphens Pharma announced its partnership with 7-Eleven to offer Ocean Health supplements at selected convenience stores in Singapore, the entrance of Ceradan range into five Middle Eastern markets through exclusive distributorship with Cooper Pharma S.A.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: SBRMagazine - 🏆 13. / 51 Read more »
Source: SBRMagazine - 🏆 13. / 51 Read more »